Abstract
There is an urgent need to develop sensitive, non-invasive biomarkers that can track airway inflammatory activity for patients with cystic fibrosis (CF). Urinary GSA levels correlate well with GSA levels in BAL samples and other markers of neutrophilic inflammation, suggesting that this biomarker may be suitable for tracking disease activity in this population.
We recruited 102 children (median 11.5 years-old) and 64 adults (median 32.5 years-old) who were admitted to hospital for management of an acute pulmonary exacerbation and/or eradication of infectious agents such as P. aeruginosa or S. aureus. Our aim was to explore how urinary GSA levels changed across admission timepoints. Urine samples were collected at admission and discharge, and GSA measured by liquid chromatography with mass spectrometry. Paired admission-discharge results were compared using Wilcoxon signed-rank test.
Paired admission-discharge samples were available for 49 children and 60 adults. A statistically significant difference was observed between admission-discharge for children, but not for adults. Spearman’s correlation analysis identified a correlation between urinary GSA levels and age, sex, inflammatory markers, and P. aeruginosa infection for children only. Our preliminary findings suggest that urinary GSA is responsive to the resolution of an acute pulmonary exacerbation and therefore warrants further studies in this population.
Competing Interest Statement
TL Blake holds a Childrens Hospital Foundation ECR Fellowship for salary support and an Australian CFA Research Trust Innovation Grant for unrelated research. PD Sly holds NHMRC Investigator and Clinical Trials & Cohort Study grants. Authors CE Wainwright and SC Bell have received institutional payments for chairing and speaking at educational events (Vertex Pharmaceuticals). CE Wainwright also declares participating in steering committee and advisory board sessions for Vertex Pharmaceuticals. N Dickerhof holds a Sir Charles Hercus Research Fellowship from the Health Research Council of New Zealand. Remaining authors Andersen, Reid and Kettle declare that they have no conflicts of interest.
Funding Statement
This study was funded by the Cystic Fibrosis Foundation (USA, SLY18KO) and Children's Hospital Foundation (AUS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Children's Health Queensland Hospital and Health Service Human Research Ethics Committee gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Author Contact Details: t.blake{at}uq.edu.au; p.sly{at}uq.edu.au; i.andersen{at}uq.edu.au; claire.wainwright{at}health.qld.gov.au; david.reid{at}health.qld.gov.au; scott.bell{at}health.qld.gov.au; tony.kettle{at}otago.ac.nz; nina.dickerhof{at}otago.ac.nz
Data Availability
All data produced in the present study are available upon reasonable request to the authors.